Peñas-Lledó E, Guillaume S, Naranjo M E G, Delgado A, Jaussent I, Blasco-Fontecilla H, Courtet P, LLerena A
CICAB Clinical Research Center, Extremadura University Hospital & Medical School, Badajoz, Spain.
1] CHU Montpellier, Hôpital Lapeyronie, Psychiatric Emergency and Post Emergency Department, Pole Urgence, Montpellier, France [2] Inserm, U1061 Montpellier, France [3] Université Montpellier I, Montpellier, France.
Pharmacogenomics J. 2015 Apr;15(2):172-6. doi: 10.1038/tpj.2014.42. Epub 2014 Aug 12.
This study examined, for the first time, whether a high CYP2D6-CYP2C19 metabolic capacity combination increases the likelihood of suicidal intent severity in a large study cohort. Survivors of a suicide attempt (n=587; 86.8% women) were genotyped for CYP2C19 (*2, *17) and CYP2D6 (*3, *4, *4xN, *5, *6, *10, wtxN) genetic variation and evaluated with the Beck Suicide Intent Scale (SIS). Patients with a high CYP2D6-CYP2C19 metabolic capacity showed an increased risk for a severe suicide attempt (P<0.01) as measured by the SIS-objective circumstance subscale (odds ratio (OR)=1.37; 95% confidence interval (CI)=1.05-1.78; P=0.02) after adjusting for confounders (gender, age, level of studies, marital status, mental disorders, tobacco use, family history of suicide, personal history of attempts and violence of the attempt). Importantly, the risk was greater in those without a family history of suicide (OR=1.82; CI=1.19-2.77; P=0.002). Further research is warranted to evaluate whether the observed relationship is mediated by the role of CYP2D6 and CYP2C19 involvement in the endogenous physiology or drug metabolism or both.
本研究首次在一个大型研究队列中检验了CYP2D6 - CYP2C19高代谢能力组合是否会增加自杀意图严重程度的可能性。对自杀未遂幸存者(n = 587;86.8%为女性)进行CYP2C19(*2,*17)和CYP2D6(*3,*4,*4xN,*5,*6,*10,wtxN)基因变异基因分型,并使用贝克自杀意图量表(SIS)进行评估。在调整混杂因素(性别、年龄、学历水平、婚姻状况、精神障碍、吸烟情况、自杀家族史、既往自杀未遂史以及此次自杀未遂的暴力程度)后,CYP2D6 - CYP2C19高代谢能力的患者经SIS客观情况子量表测量显示自杀未遂严重程度增加的风险(P < 0.01)(优势比(OR)= 1.37;95%置信区间(CI)= 1.05 - 1.78;P = 0.02)。重要的是,在没有自杀家族史的人群中风险更高(OR = 1.82;CI = 1.19 - 2.77;P = 0.002)。有必要进行进一步研究以评估所观察到的关系是否由CYP2D6和CYP2C19参与内源性生理过程或药物代谢或两者共同作用介导。